This article first appeared on GuruFocus .
Release Date: November 14, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
Positive Points
-
Akums Drugs and Pharmaceuticals Ltd ( BOM:544222 ) has entered into a joint venture with the Zambian government to set up a manufacturing plant, which is expected to drive long-term growth.
-
The company achieved a milestone by dispatching its first commercial supply of Depak glycogen tablets to Switzerland, indicating progress in its European expansion.
-
The domestic branded formulation business showed a revenue growth of 5.3% year on year, with robust portfolio margins of 21.6%.
-
Akums Drugs and Pharmaceuticals Ltd ( BOM:544222 ) has a strong cash position with net cash over INR 1,600 crores, providing leverage for organic and inorganic growth opportunities.
-
The company is focusing on higher gross margin portfolios and cost optimization initiatives in its API business, aiming for improved performance by year-end.
Negative Points
-
Revenue for Q2 FY26 saw a decline of 1.5% year on year, with operating EBITDA declining by 22% due to operating leverage issues.
-
Margins were negatively impacted by a continued downward trend in API prices, with a year-on-year drop of around 8% for top 200 APIs.
-
The international branded formulation business experienced a decline of 14.3% year on year, affected by seasonal factors.
-
The company's CDMO business margins fell sharply due to slower than expected ramp-up of new facilities and higher overheads.
-
Capacity utilization remains below optimal levels, with current operations at 40% and potential peak capacity at 55%, indicating underutilization of existing resources.
Q & A Highlights
-
Warning! GuruFocus has detected 2 Warning Sign with BOM:544222.
-
Is BOM:544222 fairly valued? Test your thesis with our free DCF calculator.
Q: Can you provide an update on the developments in the European market, particularly regarding the expansion of contracts and GMP certifications? A: Unidentified_7: We have undergone a European GMP audit for our plant and expect approval in Q4. We dispatched our first commercial supply of Depak glycogen tablets to Switzerland and expect Reverban tablet supply to Europe in Q3. We have a healthy pipeline with over 1,010 dossiers in API and have filed CP for oxygen exitel andoxin proxitil in Europe.
Q: What is the outlook for the API business, especially with the start of supplies to Europe? A: Unidentified_7: We have filed two CEPs in Europe and expect approval in the next six months. We anticipate higher gross margins in Europe. Although there was a significant EBITDA drain in the first half, we expect optimizations in gross margins and operating expenses to improve the situation in the second half.
Q: How will the Zambia project be reflected in the financials, and what is the expected market share? A: Unidentified_7: The Zambia project will be part of our CDMO business. We expect to hold a 12.5% market share in Zambia. Initially, we have a $50 million contract over two years, and once the plant is operational, we anticipate a market opportunity of $200 to $250 million.
Q: Can you explain the significant drop in EBITDA margins for Q2, and what is the outlook for H2? A: Unidentified_7: The drop in EBITDA margins is primarily due to an 8% decline in API prices, which directly impacts our margins. Additionally, new facilities have increased overheads. We expect H2 margins to be similar to H1 as we implement cost efficiency measures and stabilize product mix.
Q: What are the plans for capacity utilization and future CapEx? A: Unidentified_7: We are currently operating at 40% capacity, with a potential peak of 55%. We are focusing on better product mix and client penetration to increase utilization. CapEx is being directed towards R&D and European contracts, with a mindful approach to future investments.
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
